For Personal Use. Mass Reproduce Only with Permission from Mayo Clinic Proceedings a . Original Article Mayo Genome Consortia: a Genotype-phenotype Resource for Genome-wide Association Studies with an Application to the Analysis of Circulating Bilirubin Levels

OBJECTIVE To create a cohort for cost-effective genetic research, the Mayo Genome Consortia (MayoGC) has been assembled with participants from research studies across Mayo Clinic with high-throughput genetic data and electronic medical record (EMR) data for phenotype extraction. PARTICIPANTS AND METHODS Eligible participants include those who gave general research consent in the contributing studies to share high-throughput genotyping data with other investigators. Herein, we describe the design of the MayoGC, including the current participating cohorts, expansion efforts, data processing, and study management and organization. A genome-wide association study to identify genetic variants associated with total bilirubin levels was conducted to test the genetic research capability of the MayoGC. RESULTS Genome-wide significant results were observed on 2q37 (top single nucleotide polymorphism, rs4148325; P=5.0 × 10(-62)) and 12p12 (top single nucleotide polymorphism, rs4363657; P=5.1 × 10(-8)) corresponding to a gene cluster of uridine 5'-diphospho-glucuronosyltransferases (the UGT1A cluster) and solute carrier organic anion transporter family, member 1B1 (SLCO1B1), respectively. CONCLUSION Genome-wide association studies have identified genetic variants associated with numerous phenotypes but have been historically limited by inadequate sample size due to costly genotyping and phenotyping. Large consortia with harmonized genotype data have been assembled to attain sufficient statistical power, but phenotyping remains a rate-limiting factor in gene discovery research efforts. The EMR consists of an abundance of phenotype data that can be extracted in a relatively quick and systematic manner. The MayoGC provides a model of a unique collaborative effort in the environment of a common EMR for the investigation of genetic determinants of diseases.

[1]  L. Almasy,et al.  Genetic influences on serum bilirubin in American Indians: The strong heart family study , 2011, American journal of human biology : the official journal of the Human Biology Council.

[2]  Y. Sugiyama,et al.  Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. , 2004, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  Tae-Wook Kang,et al.  Genome-wide association of serum bilirubin levels in Korean population. , 2010, Human molecular genetics.

[4]  F. Kronenberg,et al.  Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease , 2008, Experimental Gerontology.

[5]  Geoffrey S. Tobias,et al.  Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer , 2009, Nature Genetics.

[6]  F. Kronenberg,et al.  Association Between the UGT 1 A 1 * 28 Allele , Bilirubin Levels , and Coronary Heart Disease in the Framingham Heart Study , 2006 .

[7]  Ming-Huei Chen,et al.  Genome-wide association meta-analysis for total serum bilirubin levels. , 2009, Human molecular genetics.

[8]  Wei Zhang,et al.  OATP1B1 POLYMORPHISM IS A MAJOR DETERMINANT OF SERUM BILIRUBIN LEVEL BUT NOT ASSOCIATED WITH RIFAMPICIN‐MEDIATED BILIRUBIN ELEVATION , 2007, Clinical and experimental pharmacology & physiology.

[9]  Eric Boerwinkle,et al.  The gene, environment association studies consortium (GENEVA): maximizing the knowledge obtained from GWAS by collaboration across studies of multiple conditions , 2010, Genetic epidemiology.

[10]  G. Abecasis,et al.  Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. , 2009, Human Molecular Genetics.

[11]  E. Fisher,et al.  Haplotypes in the UGT1A1 gene and their role as genetic determinants of bilirubin concentration in healthy German volunteers. , 2009, Clinical biochemistry.

[12]  R. Tukey,et al.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease. , 2000, Annual review of pharmacology and toxicology.

[13]  Sien‐Sing Yang,et al.  Genetic factors related to unconjugated hyperbilirubinemia amongst adults , 2005, Pharmacogenetics and genomics.

[14]  C. Guha,et al.  Role of cysteine residues in the function of human UDP glucuronosyltransferase isoform 1A1 (UGT1A1). , 2005, The Biochemical journal.

[15]  Jin Fan,et al.  Leveraging informatics for genetic studies: use of the electronic medical record to enable a genome-wide association study of peripheral arterial disease , 2010, J. Am. Medical Informatics Assoc..

[16]  A. Whittemore,et al.  UDP-Glucuronosyltransferase 1A1 Gene Polymorphisms and Total Bilirubin Levels in an Ethnically Diverse Cohort of Women , 2007, Drug Metabolism and Disposition.

[17]  J. Vaupel,et al.  Evidence for a substantial genetic influence on biochemical liver function tests: results from a population-based Danish twin study. , 2001, Clinical chemistry.

[18]  M. Xiong,et al.  Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population , 2009, Pharmacogenetics and genomics.

[19]  Wendy A. Wolf,et al.  The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies , 2011, BMC Medical Genomics.

[20]  Wei Zheng,et al.  A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33 , 2010, Nature Genetics.

[21]  Florian Kronenberg,et al.  Association Between the UGT1A1*28 Allele, Bilirubin Levels, and Coronary Heart Disease in the Framingham Heart Study , 2006, Circulation.